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A prospective study of high-risk commercial sex workers in Senegal
has shown that HIV-2 infection may reduce the risk of subsequent
HIV-1 infection; these findings have been confirmed and extended,
now with 13 years of observation. While exploring the biological
mechanisms behind this natural protection, we found that a
significant proportion of peripheral blood mononuclear cells ob-
tained from HIV-2-infected subjects resisted in vitro challenge with
CCR5-dependent HIV-1 viruses but not CXCR4-dependent viruses.
High levels of b-chemokines, the natural ligands of the CCR5
coreceptor, were correlated with low levels of viral replication, and
resistance was abrogated by antibodies to b-chemokines. Our
results suggest that b-chemokine-mediated resistance may be an
important correlate of HIV protection against HIV-1 infection and
relevant to HIV vaccine design.
HIV-2 has ’50% genetic homology to the prototype AIDSvirus, HIV-1. Despite structural and functional similarities,
transmission is less efficient, and progression to AIDS is signif-
icantly slower for HIV-2 than HIV-1 (1, 2). Based on these
attenuated properties, it was hypothesized that HIV-2 might
confer some protection against the more virulent HIV-1. In-
deed, epidemiological analysis of HIV-1 incidence rates in a
large cohort study of female sex workers who were exposed to
both HIV-1 and HIV-2 revealed that the risk for HIV-1 infection
in individuals infected with HIV-2 was reduced dramatically (3).
Follow up of this cohort has continued to demonstrate HIV-1
protection, ranging from 52% to 74%, depending on the study
design (4, 5).
Few studies have investigated the mechanisms by which HIV-2
infection might alter the natural course of HIV-1 infection. In
vitro studies have demonstrated that HIV-2 can inhibit HIV-1
replication by interfering with an unidentified molecular path-
way at the intracellular level (6, 7). Recently, it was shown that
the TAR region from the HIV type 2 (HIV-2) could suppress
HIV-1 transcription and replication and that HIV-2 RNA could
therefore act as an inhibitor of HIV-1 in coinfected cells (8).
Receptor-mediated viral interference would be another mech-
anism whereby both viruses compete for the same target cell
receptor, and infection with one virus might down-regulate the
receptor preventing superinfection (9). However, the small
fraction of HIV-infected cells in vivo would seem to preclude the
feasibility of such mechanisms. Robust and cross-reactive hu-
moral and cellular immunity conferred by HIV-2 infection in
people has been documented and may also play an important
role in altering susceptibility to subsequent HIV-1 infection
(10–12).
To identify mechanisms of HIV protection further, we eval-
uated the susceptibility of HIV-2-infected peripheral blood
mononuclear cells (PBMCs) to HIV-1 challenge in vitro. The
relative susceptibility of PBMCs to HIV infection has been used
to identify andyor verify inherent or acquired in vivo resistance
in exposed uninfected individuals (13–15) and clinical progres-
sion in patients infected with HIV-1 (16) and has also been used
as a potential marker of vaccine efficacy (15). The in vitro assay
allowed us to manipulate and evaluate the specific contribution
of various cell subpopulations in response to virus exposure and
infection.
Methods
Study Subjects. Our study subjects are members of the previ-
ously described cohort of registered commercial sex workers in
Dakar, Senegal (1, 2). Study participants were enrolled after
receiving informed consent, and we obtained peripheral blood
samples from 28 asymptomatic HIV-2-infected and 12 HIV-
negative individuals. Seven normal U.S. blood donors were
also included in the study as controls for cell manipulation and
storage conditions. CD4 counts determined by f luorescence-
activated cell sorter analysis (Facscount, Becton Dickinson)
and years of positivity are provided in Table 1. Serostatus was
defined by HIV-1 and HIV-2 immunoblot and confirmed with
recombinant envelope peptides and HIV-specific PCR
(17, 18).
Cell Separation. Blood was collected on EDTA. PBMCs were
obtained by centrifugation on lymphocyte separation medium
(ICN) and subsequently cryopreserved in 90% (vol/vol) FCSy
10% (vol/vol) DMSO.
Infection. For each experiment, cells were stimulated for 48 h with
5 mgyml phytohemagglutinin (PHA) in complete IL-2 medium
[RPMI medium 1640 supplemented with 20% (volyvol) FBS, 1%
antibiotics, and 100 unitsyml IL-2]. PHA was then removed, and
the cells were counted. Cell viability was evaluated by trypan
blue exclusion dye, and cultures were set up in 96-well micro-
plates at a density of 250,000 cells per 200 ml of complete IL-2
medium. All viral stocks were propagated in PBMCs from
normal donors, harvested at the peak of infection, and stored
aliquoted at 275°C. Infectivity titers were determined simulta-
neously for all viruses in the present study with serial 4-fold
dilutions in PBMCs from one donor. Cell cultures were inocu-
lated with 600 tissue culture 50% infective dose (TCID50) of each
virus, marking day 0 of the experiment. On day 2, cells were
washed with 50 times their volume of complete medium. There-
after, cell cultures were sampled and fed with 50% replacement
of the total culture volume at days 4, 7, 10, 14, and 18, unless
otherwise indicated. HIV-1 replication was assessed by p24
ELISA in culture supernatants (NEN). When sufficient cells
were available, the viral challenge experiments were performed
in duplicate.
b-Chemokines. Cells were stimulated with PHA for 2 days and
placed in culture at a density of 1 3 106 cells per ml. b-Che-
mokine levels were determined in culture supernatants by
ELISA (R & D Systems) at day 4 of the experiment.
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CD8 Depletion. CD8 depletion (.90%) was performed with the
use of antibody-coated MACS microbeads (Miltenyi Biotec,
Auburn CA) followed by magnetic separation according to the
manufacturer’s instructions.
Antibody Neutralization of b-Chemokines. A mixture of polyclonal
affinity-purified antibodies against b-chemokines at a concen-
tration of 50 mgyml each or control goat Ig at a concentration of
150 mgyml (R & D Systems) was supplied at the time of viral
challenge and at each subsequent replacement of culture me-
dium during the 18 days of the experiment. Viral replication
kinetics, after challenge of 250,000 resistant PBMCs derived
from individuals infected with HIV-2 (n 5 6) with 600 TCID50
of HIV-1JR-CSF, were observed in the presence of b-chemo-
kine-neutralizing antibodies or control antibody.
Statistics. Statistical analysis was performed with STATA (version
4.0, Stata, College Station, TX).
Results
The initial screening for resistance among the HIV-2-infected
PBMCs was performed by challenge with a macrophage-tropic
HIV-1 strain (JR-CSF), considered to be representative of NSI
strains implicated in heterosexual transmission (19, 20). HIV-
1JR-CSF uses the CCR5 as a major coreceptor for entry and has
been used in various studies to screen for resistance among
exposed uninfected individuals and HIV-1-infected long-term
nonprogressors (13, 21, 22). PBMCs from all 19 HIV-negative
controls were found to be readily infectable by HIV-1JR-CSF,
although variable in their peak levels of infection. However, a
clear difference in infectivity was observed when the HIV-2-
infected PBMCs were challenged similarly with HIV-1JR-CSF.
Cultures with a p24 antigen level of 5,000 pgyml or lower at day
10 were classified as resistant cultures in the HIV-2-infected
PBMCs. This cut-off value also represented 98% inhibition of
the median value obtained from controls. Of 28 (50%) HIV-2
PBMCs, 14 exhibited this resistant phenotype compared with
none of the 19 HIV negative PBMCs (Fisher exact test, P 5
0.002; Table 1). Viral replication kinetics indicated that resistant
and susceptible cultures had reached a plateau of infection
during the 18-day period of observation (Table 1 and Fig. 1).
When the same PBMCs were challenged with a 600 TCID50
viral inoculum of HIV-1IIIB, a CXCR4-dependent (X4) virus,
the results were strikingly different. Of 28 cases of HIV-2-
infected PBMCs, 26 supported replication of this T tropic virus
just as well as the control PBMCs (Fig. 1). The remaining two
cases exhibited peak p24 levels more than 1 log higher with
HIV-1IIIB than with HIV-1JR-CSF. As such, HIV-1IIIB rep-
licated freely, unlike HIV-1JR-CSF which seemed to be inhib-
ited by HIV-2 infection. The infectability of the PBMCs, as
demonstrated by their susceptibility to the T tropic X4 virus,
showed that the intrinsic ability of the PBMCs to support viral
replication remained intact and that resistance was probably not
associated with CD4, the primary cellular receptor for viral
entry.
Because target cell viability is critical to viral replication, we
repeatedly evaluated parallel uninfected cultures for cell count
and cell viability over time. We were unable to demonstrate any
consistent differences in cell numbers or viability between
HIV-2-infected and HIV-negative PBMCs or between resistant
and susceptible cells within the group of HIV-2-infected samples
(data not shown). Furthermore, the ability of all HIV-2 PBMCs
to support HIV-1IIIB virus infection suggested that resistance
was not due to cell viability differences. Because ex vivo pro-
duction of endogenous HIV-2 might interfere with the infection
of a related retrovirus, parallel noninoculated cultures of the
HIV-2 PBMCs were assayed over time for endogenous HIV-2
production with a simian immunodeficiency virus core antigen
ELISA (Coulter). However, no detectable levels of p26 were
found. The potency of the resistance was evaluated with 10-fold
higher inoculum doses of HIV-1, and another CCR5-NSI virus
was also evaluated in limited studies with essentially the same
results (data not shown). In addition, we recently described in
nine other individuals infected with HIV-2 similar observations
with two different isolates: X4yR5 isolate HIV-1MN and R5
isolate HIV-1BAL (15).
We also sought to evaluate characteristics of the study subjects
that might be associated with in vitro resistance. CD41 cell
counts determined within 1 year of the PBMC collection did not
seem to correlate with the resistance phenotype (Table 1).
Similarly, the minimum time infected, defined by the difference
between sample date and seroconversion date or first sample
date in the case of prevalent individuals, did not differ between
the two groups (Table 1). Thus, it seemed that the observed
HIV-1 resistance was specific to CCR5-dependent (R5) viruses
and that this resistance was not due to altered cell viability,
endogenous HIV-2 production, or definable characteristics of
the individuals infected with HIV-2.
The two most widely used coreceptors for HIV-1 are CCR5
and CXCR4, expressed by both activated T lymphocytes and
mononuclear phagocytes. CCR5 is the natural receptor for the
b-chemokines RANTES, MIP-1a, and MIP-1b and also serves
as the HIV coreceptor preferentially used by NSI strains of
HIV-1 and HIV-2 (23–28). CXCR4, a receptor for the CXC
chemokine SDF-1, is used by MT2 tropic or SI strains of HIV-1
and some HIV-2 strains (29), although HIV-2 is considered to
Table 1. HIV-1 JR-CSF infectability of PBMCs from HIV-2-infected
individuals
Patient
identification
no.
Peak p24,
pg/ml
Positive
years CD41 Phenotype
2602 10 4 744 R
2 13 5 483 R
1082 33 9 184 R
31 58 7 458 R
2269 131 5 689 R
342 230 11 603 R
1704 374 6 1,027 R
879 571 9 ND R
636 619 5 1,285 R
1503 830 5 1,089 R
1972 1,520 ,1 1,182 R
2712 1,936 5 577 R
1079 3,462 3 1,030 R
82 4,889 11 1,647 R
22 9,984 8 899 S
337 35,883 6 522 S
912 49,032 11 671 S
2378 55,600 4 1,162 S
2028 60,117 9 1,475 S
1960 85,200 6 728 S
2822 101,911 4 ND S
3199 103,439 2 ND S
996 122,065 7 611 S
1814 146,433 10 1,095 S
2661 176,815 5 1,198 S
524 198,968 11 1,451 S
288 643,919 9 905 S
1130 647,340 8 854 S
Positive years, difference between sample year and infection date (when
known) or date of the first positive bleed. CD41, CD41 cell counts within 1
year of sample collection. ND, not determined; R, resistance (peak p24 levels
,5,000 pgyml); S, susceptibility.
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be more promiscuous in its coreceptor usage (27, 28, 30–32). In
1995, Cocchi and colleagues (33) described suppression of HIV
replication by CD81 T cells from individuals infected with HIV
mediated by the b-chemokines RANTES, MIP-1a, and MIP-1b;
potent and specific suppression of various HIV-1, HIV-2, and
simian immunodeficiency virus strains was mediated by blockage
of the critical viral coreceptors.
In our study, it seemed that HIV-2-associated resistance to
HIV-1 depended on the strain of HIV-1, preferentially associ-
ated with R5 as opposed to X4 strains. Therefore, we suspected
that resistance was mediated via blocking of the R5 coreceptors
by their natural ligands, the b-chemokines (23–28). Levels of
RANTES, MIP-1a, and MIP-1b were determined after PHA
stimulation in parallel uninfected cultures of the same HIV-2-
Fig. 2. b-Chemokine production inversely correlates with resistance of PBMCs to HIV-1JR-CSF infection. MIP-1a, MIP-1b, and RANTES production in vitro by
PBMCs was inversely correlated with the ability of the same cells to support replication of HIV-1JR-CSF as determined by p24 levels (dark bars) at day 7 after viral
challenge. There was an inverse correlation between b-chemokine and p24 levels [Spearman’s correlation test for MIP-1a (P 5 0.009), for MIP-1b (P 5 0.03), and
for RANTES (P 5 0.04)].
Fig. 1. In vitro infectability of PBMCs from individuals infected with HIV-2 or controls by different strains of HIV-1. (A) PBMCs from individuals infected with
HIV-2 (n 5 28) or controls (n 5 19) were challenged with 600 TCID50 of HIV-1JR-CSF or HIV-1IIIB and monitored for p24 production over a period of 18 days. Values
presented correspond to p24 levels at day 10. HIV-1JR-CSF infection levels in HIV-2-infected PBMCs were significantly lower than those with HIV-1IIIB (Wilcoxon
rank-sum test, P 5 0.0001). (B) Replication kinetics of HIV-1JR-CSF (filled squares) and HIV-1IIIB (open circles) in PBMCs from individuals infected with HIV-2 that
were found to be resistant to HIV-1JR-CSF (Left; n 5 14) or susceptible (Center; n 5 14) and from negative controls (Right; n 5 19). The median values and the
first and third quartiles are plotted.
Kokkotou et al. PNAS u June 6, 2000 u vol. 97 u no. 12 u 6799
M
IC
RO
BI
O
LO
G
Y
infected PBMCs that were challenged with HIV-1JR-CSF. We
were able to demonstrate a strong inverse correlation between
all three b-chemokines measured at day 4 and p24 production in
culture supernatants infected with HIV-1JR-CSF at days 7 and
10 of the experiment (Fig. 2). Most resistant PBMCs derived
from individuals infected with HIV-2 clustered together as high
b-chemokine producers, whereas susceptible PBMCs produced
relatively less b-chemokines.
Having demonstrated that PBMCs derived from individuals
infected with HIV-2 secreted increased levels of b-chemokines
after stimulation with PHA, we sought to delineate and char-
acterize further the role of b-chemokines in mediating HIV-1
resistance observed in our system. Although the b-chemokines
might be the major suppressors of M tropic virus replication,
other immune mechanisms or cellular factors may also affect the
replication of M tropic viruses, accounting for the resistance we
identified. For example, a 32-bp deletion in the CCR5 corecep-
tor has been associated with resistance to infection by macro-
phage tropic strains of HIV-1 (13, 34). In the African popula-
tions studied, this mutation is relatively rare, and we have
confirmed this rarity independently by PCR genotypic analysis of
the CCR5 receptor in our Senegalese study population (35).
Thus, excess b-chemokine production from HIV-2-infected
PBMCs did not seem to be due to a mutant CCR5 receptor.
Several studies have shown that both soluble and cell contact-
dependent factors contribute to the HIV suppressive effects of
CD81 T cells (21, 22, 36, 37). Because CD81 cells were
considered to be a significant source of b-chemokines (13, 14,
33), it was conceivable that their depletion from the resistant
HIV-2-infected PBMCs might counteract the resistance to HIV-
1JR-CSF. Indeed, we observed a remarkable increase in p24
production after the removal of CD81 cells from five HIV-2-
infected PBMC cultures (Fig. 3A). However, the depletion of
CD81 cells did not return the cells to 100% susceptibility (data
not shown). Within the PBMC cell population, cells other than
CD81 cells may be capable of producing b-chemokines, includ-
ing both monocytes and natural killer cells (38–40). b-Chemo-
kines also seem to be expressed as part of the cell-mediated
response to HIV infection including the generation of prolifer-
ative and cytotoxic responses. After antigen-specific activation of
CD81 cytotoxic lymphocytes, b-chemokines bound to sulfated
proteoglycans are secreted from cytolytic granules with gran-
zyme A. Both granzyme A and b-chemokines are capable of
inhibiting HIV-1 infection (21, 22), thereby enabling CD81 cells
to exert an antiviral effect through lysis of infected cells as well
as inhibition of free virus (21, 22).
We subsequently followed two different experimental ap-
proaches to clarify further the role of b-chemokines in the
observed resistance to HIV-1JR-CSF infection. First, we hy-
pothesized that if the resistance was mediated by b-chemokines
or another soluble factor, then we could provide them to
otherwise susceptible PBMCs and expect the cells to exhibit a
resistant phenotype. Indeed, when previously identified resistant
PBMCs from individuals infected with HIV-2 were cultured in
the upper chamber of a trans-well system, the cell-free super-
natant significantly reduced the ability of normal susceptible
donor PBMCs to support replication of HIV-1JR-CSF (data not
shown). Although this experiment did not unambiguously dem-
onstrate that b-chemokines were the sole factors involved, it
confirmed the soluble cell-free nature of the resistance.
Second, to establish further the central role of b-chemokines
in HIV-1 resistance, we evaluated the cell susceptibility on
antibody-mediated neutralization of the b-chemokine activity.
Culture media were continuously supplied with a mixture of
polyclonal neutralizing antibodies to RANTES, MIP-1a, and
MIP-1b or control antibody, starting at the time of HIV-1JR-
CSF inoculation, and the kinetics of p24 accumulation were
assessed over time. Neutralization of b-chemokines had a dra-
matic effect on viral replication. In six of six previously resistant
HIV-2 PBMCs, there was a significant increase in HIV-1JR-CSF
infection levels with up to a 3-log increase in p24 levels (Fig. 3B).
No significant effect was observed in two control PBMC cultures
where HIV-1JR-CSF replication was already vigorous. Although
it was not possible to assess individually the contribution of each
b-chemokine to resistance caused by sample and cell number
restrictions, it is known from previous studies that the overall
activity of b-chemokines is synergistic (21, 22, 33, 38–40). The
peak p24 levels that were achieved in some HIV-2-infected
PBMC cultures after b-chemokine neutralization were still lower
Fig. 3. Role of b-chemokines in HIV-1JR-CSF resistance in vitro exhibited by
HIV-2 PBMCs. (A) PBMCs (filled squares) and the CD8-depleted fraction (open
squares) derived from five individuals infected with HIV-2 were challenged
with 600 TCID50 of HIV-1JR-CSF, and p24 production was monitored for 14
days. (B) Antibody neutralization of RANTES, MIP-1a, and MIP-1b abrogated
the HIV-2-associated resistance to R5 HIV-1 virus. Viral replication kinetics,
after challenge of 250,000 resistant PBMCs derived from individuals infected
with HIV-2 (n 5 6) with 600 TCID50 of HIV-1JR-CSF, were observed in the
presence of b-chemokine-neutralizing antibodies (open diamonds) or control
antibody (filled squares); median and first and third quartiles are shown. For
clarity of presentation, p24 levels ,50 pgyml were assigned a value of 50
pgyml.
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than those obtained from control PBMCs. It is likely that the
residual resistance could be attributed to incomplete b-chemo-
kine neutralization andyor the presence of non-b-chemokine
mediators. Our results would also be compatible with the
presence and activity of as-yet unidentified b-chemokine(s) that
our antibody treatment could not neutralize. It has been re-
ported recently that certain viruses such as cytomegalovirus and
human herpesvirus-8 encode chemokine-like molecules (41, 42).
Because HIV-2 infection might render the host more susceptible
to such pathogens, this scenario represents an intriguing possible
explanation of our results. In two resistant HIV-2 PBMCs,
b-chemokine antibodies were added to the cell culture, either at
the initial viral challenge and at each subsequent feeding or once
at the time of challenge, resulting in similar effects on viral
replication (data not shown). This experiment implies that the
effect of b-chemokines is exerted at viral entry and that the cells
that are infected initially are those responsible for the majority
of p24 production.
Discussion
The elucidation of the potential benefit or selective advantage
that HIV-2 might gain by promoting the overproduction of
b-chemokines in host cells would help to explain the phenom-
enon of resistance that we describe in the present study. The
coreceptor requirements for HIV-2 or simian immunodeficiency
virus are not as stringent as with HIV-1, and redundancy is
common (27, 28, 30–32). One plausible explanation suggests that
the coreceptor promiscuity of HIV-2 is an adaptive and select-
able change whereby HIV-2 would be less susceptible to the
CCR5 blockade as mediated by excess b-chemokines. In this
way, b-chemokines would disproportionately affect HIV-1 and
have little control over HIV-2 infection. Alternatively, b-che-
mokine overproduction could have an effect on the in vivo
HIV-2 dynamics where significantly lower plasma viral loads are
independent of sufficient proviral templates, consistent with
b-chemokine neutralization (43).
Although a significant proportion of individuals infected with
HIV-2 exhibited reduced susceptibility to HIV-1 challenge, the
parameters by which the resistant phenotype would be induced
in some individuals infected with HIV-2 and not in others remain
unclear. One possibility could be differences in viral load or
immune activation of the host. Alternatively, a specific HIV-2
strain or particular signature sequences might trigger the over-
production of b-chemokines. Sekigawa and colleagues (44, 45)
have demonstrated a direct interaction of the HIV-2 envelope
with the a-chain of the CD8 molecule and stimulation of
b-chemokines in contrast to the gp120 of HIV-1. Their studies
suggest that HIV-2 may possess a virus-specific mechanism for
inducing b-chemokines that would protect from subsequent
CCR5-mediated virus infection (44, 45).
Multiple lines of evidence have emerged to support the role of
b-chemokines in HIV-1 resistance among PBMCs from individ-
uals infected with HIV-2. These include the dichotomous resis-
tance of R5 vs. X4 viral strains, increased levels of b-chemokines
in cultures associated with low p24 levels, and the abrogation of
resistance by neutralizing antibodies to b-chemokines. The
involvement of b-chemokine-related mechanisms in resistance
to HIV-1 infection, aside from genetic polymorphism in the
CCR5 coreceptor (13, 33), has also been described in previous
studies. T cell clones from exposed, uninfected partners of
individuals infected with HIV-1 secreted high levels of b-che-
mokines on challenge with HIV-1-specific peptides (14). He-
mophiliacs that received HIV-1-contaminated blood products
and resisted infection were found to produce high levels of
b-chemokines in vitro (46). A role for b-chemokines has been
proposed in mechanisms of disease attenuation as well. In a
recent study, specific HIV-1 proteins prompted ample in vitro
production of b-chemokines in an HIV-1-infected hemophiliac
long-term nonprogressor (47). Lehner et al. (48) described the
successful immunization of macaques with a simian immunode-
ficiency virus env- and core-based vaccine that targeted the
mucosa. Resistance in the vaccinated monkeys and in one of the
control animals was associated with increased production of
b-chemokines. It is therefore intriguing to consider antiretrovi-
ral vaccine strategies that might incorporate b-chemokine in-
duction or coreceptor-blocking activity where the HIV-2 enve-
lope might be of use.
In summary, in vitro observations from this study have eluci-
dated an important biochemical mechanism implicated in the
protection of individuals infected with HIV-2 from subsequent
HIV-1 infection. Using an in vitro challenge system, we were able
to demonstrate that a significant percentage (50%) of PBMCs
derived from HIV-2-infected asymptomatic commercial sex
workers could not support efficient replication of an R5 HIV-1
virus. It is of note that these figures are consistent with the
epidemiological analysis, in which 52–74% of women infected
with HIV-2 were found to be resistant to HIV-1 (3–5). Thus, the
present study has described at least one potential mechanism by
which HIV-2 alters susceptibility to HIV-1. It is certainly
possible that other immune mechanisms are operative in vivo
and may also contribute to the protection that has been
observed in people. Nonetheless, these results suggest that
b-chemokines may be important correlates of HIV-1 protec-
tion as exemplified by the documented protection demon-
strated in people. These results implicate a unique mechanism
that is not only viral suppressive but that may be readily
adapted for immunoprophylaxis.
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